Achilles Therapeutics PLC (FRA:698)
€ 0.71 0 (0%) Market Cap: 30.32 Mil Enterprise Value: -69.29 Mil PE Ratio: 0 PB Ratio: 0.27 GF Score: 34/100

Achilles Therapeutics PLC at Eqt Life Sciences BioCapital Europe Transcript

Mar 09, 2023 / 01:40PM GMT
Release Date Price: €1 (+0.50%)
Unidentified Participant

(audio in progress) in the life sciences, health and technology sectors. So the first speaker that I've got the pleasure of introducing is Dr. Iraj Ali, CEO at Achilles Therapeutics. So Achilles is a Nasdaq-listed biotechnology company developing novel cancer immunotherapies. Iraj has been the CEO since 2018 and previously was a managing partner at Syncona. So [to give a quick] -- I'll hand it over to you.

Iraj Ali
Achilles Therapeutics plc - CEO

Thanks, Kate. Okay, so it looks like it's working. So thank you, everybody. Delighted to have this opportunity to tell you a little bit more about Achilles Therapeutics. This presentation is available on our website, and I urge people to read the forward-looking statements and disclaimers.

So we are a solid tumor cancer company, developing transformative medicines using precision cell therapy, which is a big mouthful to say we think that we have got a novel and breakthrough approach into treating the solid tumors. The company has two active clinical programs and substantial operations with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot